Novel approaches to treating Alzheimer's disease include early intervention
(Medical Xpress) -- Researchers at the Comprehensive Alzheimers Program at the University of California, San Diego School of Medicine have announced two new clinical trials for patients with either mild to moderate Alzheimers disease (AD) and one trial for Mild Cognitive Impairment.
Two of these studies represent an exciting new approach to treating Alzheimers, focusing on improving memory in patients with early symptoms of impaired memory and possibly slowing down the disease progression long before symptoms appear, said Michael Rafii, MD, PhD, assistant professor of neurosciences and director of the Memory Disorders Clinic at UC San Diego .
All three are randomized, double-blind, placebo-controlled studies:
The first is a national clinical trial examining the effects of resveratrol a compound found in red grapes or juice, red wine, chocolate, tomatoes and peanuts on participants with mild to moderate dementia due to Alzheimers disease. Pre-clinical and pilot clinical research studies suggest that resveratrol may prevent diabetes, act as a natural cancer fighter, ward off cardiovascular disease, and prevent memory loss, but there has been no large definitive study of its effects in humans.
The risk of all of these diseases increases with aging, said Rafii. Most resveratrol studies showing any health benefits have been conducted in animal models such as mice, and with doses that far exceed intake from sipping wine or nibbling on chocolate. With this clinical trial, we hope to find out if daily doses of pure resveratrol can delay or alter memory deterioration and daily functioning in people with mild to moderate dementia due to Alzheimers.
The second trial is a phase-two study employing an immunotherapeutic drug developed by Roche called Gantenerumab to remove beta-amyloid, a protein that is deposited into plaques found in the brains of patients with Alzheimer's disease. Beta-amyloid is neurotoxic and believed to be the main cause of neuronal degeneration in AD. This trial is for patients with what is called prodromal Alzheimers disease, or mild cognitive impairment that represents the earliest state of the disease.
The third study involves a drug called Crenezumab , which Rafii says has been shown to be one of the more potent amyloid-lowering compounds yet developed. This drug, from Genentech, is a monoclonal antibody, which means that it very specifically binds only to beta-amyloid.
By using antibodies against beta-amyloid we hope to reduce its neurotoxic effects on the brain, Rafii said. There is a lot of evidence that beta-amyloid molecules cause damaging effects in the brain perhaps as much as ten years before they deposit to form plaques and result in symptoms of memory loss. The aim of these two studies is to see if we can remove beta-amyloid before it causes damage and forms the plaques that result in Alzheimers.
According to the National Institute of Aging, more than 5.3 million people in the United States are suffering from Alzheimers, and every 70 seconds, another person develops the disease. Currently, there are no drugs to treat prodomal AD.
Provided by University of California - San Diego
- Putting top brains to the test with Alzheimer's protein Jan 31, 2011 | not rated yet | 0
- Georgetown physician leads national resveratrol study for Alzheimer's disease May 14, 2012 | not rated yet | 0
- Pulse pressure elevation could presage cerebrovascular disease in Alzheimer's patients Apr 09, 2012 | not rated yet | 0
- Scientists to test gammaglobulin treatment for Alzheimer's disease Sep 24, 2009 | not rated yet | 0
- New discovery in Alzheimer's protein puzzle May 14, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Question of reflection and transmission of TEM wave in normal incidenc
4 hours ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
5 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
6 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
11 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
Calculating on-axis elements of a solenoid
23 hours ago I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
latitude & longitude & air pressure
May 22, 2013 Hi there, I have a peculiar question. Imagine that you are in a earth position, obtained by google, that gives you the latitude and longitude....
- More from Physics Forums - Classical Physics
More news stories
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia 5 hours ago | 5 / 5 (4) | 0 |
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia 6 hours ago | not rated yet | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia 7 hours ago | 5 / 5 (1) | 1 |
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
Alzheimer's disease & dementia 10 hours ago | not rated yet | 0
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia May 21, 2013 | 5 / 5 (7) | 0 |
(HealthDay)—Type 2 diabetes is more aggressive in children than adults, with signs of serious complications seen just a few years after diagnosis, new research finds.
44 minutes ago | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
3 hours ago | 4.7 / 5 (3) | 0 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
7 hours ago | 5 / 5 (2) | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
9 hours ago | 4.9 / 5 (7) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
7 hours ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
5 hours ago | not rated yet | 0 |